Recent Posts
- RAS Inhibitor Resistance in PDAC: Insights from AACR 2025
- 92% RFS at 2 Years: PD-1 Immunotherapy for MMRd / MSI-H Tumors at AACR 2025
- Antibody-Drug Conjugates: 40 Years of Cancer Treatment Innovation
- Zongertinib 71% ORR for HER2-Mutant NSCLC: Key Insights from AACR 2025
- Pembrolizumab KEYNOTE-689 Phase 3 Trial Update for LA-HNSCC at AACR 2025
Donate
Oncology Conference Videos
Oncology News
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert…
Why isn’t CAR-T Therapy Revolutionizing the Fight Against GI Cancers? 17 Trial Insights from ASCO GI 2025
Introduction:Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025, as…
FGFR2 Mutations and IDH1 Real-World Data Suggests Caution with Immunotherapy in Specific mBTC – ASCO GI Dr. Richard Kim, MD Moffitt Cancer Center
In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP)…
EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer TreatmentThe results of the Phase 3 EMBER-3…
Featured Post
In the evolving landscape of cancer careIn the evolving landscape of cancer care, the use…
SABCS 2024
The MOASC represents a prestigious accolade designed to recognize and encourage promising young researchers in…